作者
Athol U Wells, Kevin R Flaherty, Kevin K Brown, Yoshikazu Inoue, Anand Devaraj, Luca Richeldi, Teng Moua, Bruno Crestani, Wim A Wuyts, Susanne Stowasser, Manuel Quaresma, Rainer-Georg Goeldner, Rozsa Schlenker-Herceg, Martin Kolb, S Abe, M Aburto, O Acosta, C Andrews, D Antin-Ozerkis, G Arce, M Arias, S Avdeev, A Barczyk, R Bascom, E Bazdyrev, P Beirne, E Belloli, MA Bergna, E Bergot, N Bhatt, S Blaas, B Bondue, F Bonella, E Britt, K Buch, J Burk, H Cai, A Cantin, DM Castillo Villegas, A Cazaux, S Cerri, S Chaaban, N Chaudhuri, V Cottin, B Crestani, G Criner, C Dahlqvist, S Danoff, J Dematte D'Amico, D Dilling, P Elias, N Ettinger, J Falk, ER Fernández Pérez, A Gamez-Dubuis, G Giessel, A Gifford, M Glassberg, C Glazer, J Golden, L Gómez Carrera, J Guiot, R Hallowell, H Hayashi, J Hetzel, N Hirani, L Homik, B Hope-Gill, D Hotchkin, K Ichikado, M Ilkovich, Y Inoue, S Izumi, E Jassem, L Jones, S Jouneau, R Kaner, J Kang, T Kawamura, R Kessler, Y Kim, K Kishi, H Kitamura, M Kolb, Y Kondoh, C Kono, D Koschel, M Kreuter, T Kulkarni, J Kus, F Lebargy, A León Jiménez, Q Luo, Y Mageto, TM Maher, S Makino, S Marchand-Adam, C Marquette, R Martinez, M Martínez, R Maturana Rozas, Y Miyazaki, S Moiseev, M Molina-Molina, L Morrison, L Morrow, T Moua, A Nambiar, Y Nishioka, H Nunes, M Okamoto, J Oldham, M Otaola, M Padilla, JS Park, N Patel, A Pesci, W Piotrowski, L Pitts, H Poonyagariyagorn, A Prasse, S Quadrelli, W Randerath, R Refini, M Reynaud-Gaubert, F Riviere, JA Rodríguez Portal, I Rosas, M Rossman, Z Safdar, T Saito, N Sakamoto, M Salinas Fénero, J Sauleda, S Schmidt, MB Scholand, M Schwartz, S Shapera, O Shlobin, B Sigal, A Silva Orellana, D Skowasch, JW Song, S Stieglitz, H Stone, M Strek, T Suda, H Sugiura, H Takahashi, H Takaya
发表日期
2020/5/1
期刊
The lancet Respiratory medicine
卷号
8
期号
5
页码范围
453-460
出版商
Elsevier
简介
Background
The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis.
Methods
The INBUILD trial was a randomised, double-blind, placebo-controlled, parallel group trial done at 153 sites in 15 countries. Participants had an investigator-diagnosed fibrosing ILD other than IPF, with chest imaging features of fibrosis of more than 10% extent on high resolution CT (HRCT), forced vital capacity (FVC) of 45% or more predicted, and diffusing capacity of the lung for carbon monoxide (DLco) of at least 30% and less than 80% predicted. Participants fulfilled protocol-defined criteria for ILD progression in the 24 months before screening, despite management considered appropriate in clinical practice for …
学术搜索中的文章
AU Wells, KR Flaherty, KK Brown, Y Inoue, A Devaraj… - The lancet Respiratory medicine, 2020